CIMAB

aka CIMAB S.A., Center of Molecular Immunology, Centro de Inmunología Molecular, CIM

CIMAB is the commercial arm of Havana's Center of Molecular Immunology, the Cuban institute that created the EGFR antibody nimotuzumab and the lung cancer vaccine CIMAvax-EGF.

The Center of Molecular Immunology (CIM) in Havana develops monoclonal antibodies and therapeutic vaccines, and CIMAB S.A. is the company that licenses and exports them. Nimotuzumab (h-R3), a humanised EGFR antibody with intermediate affinity that spares normal skin, is approved in Cuba, India (as BIOMAb EGFR with Biocon), China and other countries for head and neck cancer, glioma and nasopharyngeal cancer, mostly with radiotherapy. CIM also created CIMAvax-EGF, a vaccine against epidermal growth factor for non-small cell lung cancer, and the anti-idiotype vaccine racotumomab.

Headquarters

Havana, CU

Scorecard

All companies

#171of 1181 companies, score 28

targets +2
modalities +2
registry trials +24

0 approved, 0 in phase 3, 0 earlier, 1 targets, 140 registry studies. Formula on the scorecards page.

Type

biotech

Products

1top

EstablishedHumanised anti-EGFR monoclonal antibody, intravenous

Nimotuzumab · BIOMAb EGFR / TheraCIM / CIMAher

Nimotuzumab is a Cuban-developed antibody against EGFR approved in India, China, Cuba and other countries for head and neck cancer, nasopharyngeal cancer and brain tumours, usually with radiotherapy; it causes far less rash than cetuximab but has never been approved in the United States or Europe.

Connected